A pre-clinical trial conducted on
mice by Italy's Higher Health Institute (ISS) on a new COVID-19
'super-vaccine' has given positive results, according to a paper
published in the Viruses journal.
The vaccine takes a new approach as it is based on a protein
common to all the variants of SARS -CoV-2.
So it is designed to be effective against all the variants and
give lasting protection.
The tests were done by researchers from the ISS's National
Centre for Global Health (Centro Nazionale per la Salute
Globale).
ALL RIGHTS RESERVED © Copyright ANSA
